Clinical trial
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's…
NCT00134251 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00134251 |
|---|---|
| Title | Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Parallel Group Study Exploring Effects of SLV308 up to 42 mg/Day Administered as an Adjunctive Therapy to L-Dopa in Patients With Advanced Stage Parkinson's Disease |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | SLV308 |
| Start date | Oct 1, 2005 |
| First posted | Aug 24, 2005 |
| Last update posted | Jan 30, 2009 |
| Countries | Bulgaria, Malta, Serbia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: